X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare J.B.Chemicals with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

J.B.CHEMICALS vs CADILA HEALTHCARE - Comparison Results

J.B.CHEMICALS    Change

JB Chemicals and Pharmaceuticals Limited (JBCPL), the flagship of the Unique Group, is one of the India's leading transnational pharmaceutical company. The company has 11 manufacturing facilities at four locations in India (Belapur, Ankleshwar, Panol... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    J.B.CHEMICALS CADILA HEALTHCARE J.B.CHEMICALS/
CADILA HEALTHCARE
 
P/E (TTM) x 17.1 19.5 87.8% View Chart
P/BV x 2.3 4.6 50.2% View Chart
Dividend Yield % 0.2 0.9 18.9%  

Financials

 J.B.CHEMICALS   CADILA HEALTHCARE
EQUITY SHARE DATA
    J.B.CHEMICALS
Mar-16
CADILA HEALTHCARE
Mar-18
J.B.CHEMICALS/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs318558 57.0%   
Low Rs200362 55.2%   
Sales per share (Unadj.) Rs148.0116.3 127.3%  
Earnings per share (Unadj.) Rs19.117.9 106.8%  
Cash flow per share (Unadj.) Rs23.923.1 103.5%  
Dividends per share (Unadj.) Rs0.503.50 14.3%  
Dividend yield (eoy) %0.20.8 25.4%  
Book value per share (Unadj.) Rs128.985.4 151.0%  
Shares outstanding (eoy) m84.821,023.74 8.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.74.0 44.2%   
Avg P/E ratio x13.625.7 52.7%  
P/CF ratio (eoy) x10.819.9 54.4%  
Price / Book Value ratio x2.05.4 37.3%  
Dividend payout %2.619.6 13.4%   
Avg Mkt Cap Rs m21,951470,664 4.7%   
No. of employees `0002.711.8 23.1%   
Total wages/salary Rs m1,84118,545 9.9%   
Avg. sales/employee Rs Th4,590.910,072.7 45.6%   
Avg. wages/employee Rs Th673.41,569.1 42.9%   
Avg. net profit/employee Rs Th592.11,547.7 38.3%   
INCOME DATA
Net Sales Rs m12,551119,049 10.5%  
Other income Rs m5421,132 47.8%   
Total revenues Rs m13,093120,181 10.9%   
Gross profit Rs m2,05528,475 7.2%  
Depreciation Rs m4125,388 7.7%   
Interest Rs m96911 10.5%   
Profit before tax Rs m2,08823,308 9.0%   
Minority Interest Rs m0628 -0.1%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m4695,644 8.3%   
Profit after tax Rs m1,61918,292 8.8%  
Gross profit margin %16.423.9 68.4%  
Effective tax rate %22.524.2 92.8%   
Net profit margin %12.915.4 83.9%  
BALANCE SHEET DATA
Current assets Rs m7,77882,005 9.5%   
Current liabilities Rs m4,35860,720 7.2%   
Net working cap to sales %27.217.9 152.4%  
Current ratio x1.81.4 132.1%  
Inventory Days Days5573 74.7%  
Debtors Days Days8098 81.4%  
Net fixed assets Rs m5,71383,703 6.8%   
Share capital Rs m1701,024 16.6%   
"Free" reserves Rs m10,54786,421 12.2%   
Net worth Rs m10,93787,445 12.5%   
Long term debt Rs m025,551 0.0%   
Total assets Rs m15,574180,653 8.6%  
Interest coverage x22.826.6 85.8%   
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x0.80.7 122.3%   
Return on assets %11.010.6 103.6%  
Return on equity %14.820.9 70.8%  
Return on capital %20.022.0 90.8%  
Exports to sales %48.70-   
Imports to sales %7.10-   
Exports (fob) Rs m6,115NA-   
Imports (cif) Rs m889NA-   
Fx inflow Rs m6,16942,683 14.5%   
Fx outflow Rs m1,28511,242 11.4%   
Net fx Rs m4,88431,441 15.5%   
CASH FLOW
From Operations Rs m1,3979,193 15.2%  
From Investments Rs m-320-9,737 3.3%  
From Financial Activity Rs m-1,196515 -232.2%  
Net Cashflow Rs m-102-29 352.8%  

Share Holding

Indian Promoters % 55.4 74.8 74.1%  
Foreign collaborators % 0.3 0.0 -  
Indian inst/Mut Fund % 3.4 8.3 40.8%  
FIIs % 3.9 5.9 66.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 37.0 11.0 336.4%  
Shareholders   30,437 44,069 69.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare J.B.CHEMICALS With:   VENUS REMEDIES  ORCHID PHARMA LTD  SANOFI INDIA  TTK HEALTHCARE  SHASUN PHARMA  

Compare J.B.CHEMICALS With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

CADILA HEALTHCARE 2017-18 Annual Report Analysis (Annual Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

Here's an analysis of the annual report of CADILA HEALTHCARE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

CADILA HEALTHCARE Announces Quarterly Results (1QFY19); Net Profit Up 274.4% (Quarterly Result Update)

Aug 14, 2018 | Updated on Aug 14, 2018

For the quarter ended June 2018, CADILA HEALTHCARE has posted a net profit of Rs 4 bn (up 274.4% YoY). Sales on the other hand came in at Rs 29 bn (up 29.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

J.B.CHEMICALS SHARE PRICE


Sep 21, 2018 (Close)

TRACK J.B.CHEMICALS

  • Track your investment in J.B.CHEMICALS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

J.B.CHEMICALS 5-YR ANALYSIS

COMPARE J.B.CHEMICALS WITH

MARKET STATS